Naveen Pemmaraju: MPN AYA state-of-the-art review
Naveen Pemmaraju shared a post on X:
“MPN AYA state-of-the-art review led by Hannah Goulart and Naveen Pemmaraju.”
Source: Naveen Pemmaraju/X
Authors: Hannah Goulart, Lucia Masarova, Ruben Mesa, Claire Harrison, Jean-Jacques Kiladjian and Naveen Pemmaraju.
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.